Opinion|Videos|September 20, 2024
Role of Histology and Data in Selecting Optimal Therapy in nccRCC
Medical experts explore how non–clear cell RCC histology impacts treatment selection, addressing challenges with less common subtypes vs more frequent ones, and discuss how clinical data and experience inform treatment sequencing and shared decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does the histology of nccRCC affect treatment selection?
What challenges are often faced when treating a patient with a less frequent subtype (collecting duct, renal medullary) vs.vs a more frequent subtype (papillary, chromophobe)?
- How do you utilize both clinical data and experience in your approach to treatment sequencing?
How do you facilitate shared discussion decision-making in treatment selection?
Advertisement
Related to this article
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
3
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
4
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
5